181 related articles for article (PubMed ID: 24950363)
1. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Ku Z; Liu Q; Ye X; Cai Y; Wang X; Shi J; Li D; Jin X; An W; Huang Z
Vaccine; 2014 Jul; 32(34):4296-303. PubMed ID: 24950363
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease.
Liu D; Leung K; Jit M; Yu H; Yang J; Liao Q; Liu F; Zheng Y; Wu JT
Clin Microbiol Infect; 2020 Mar; 26(3):373-380. PubMed ID: 31279839
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Characterization of Neutralizing Hen Antibodies to
Mwale PF; Lee CH; Huang PN; Tseng SN; Shih SR; Huang HY; Leu SJ; Huang YJ; Chiang LC; Mao YC; Wang WC; Yang YY
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923724
[No Abstract] [Full Text] [Related]
4. Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice.
Li YX; Zhao H; Cao RY; Deng YQ; Han JF; Zhu SY; Ma J; Liu L; Qin ED; Qin CF
Virol J; 2014 May; 11():79. PubMed ID: 24885030
[TBL] [Abstract][Full Text] [Related]
5. An enterovirus A71 virus-like particle with replaced loops confers partial cross-protection in mice.
Liu X; Zhu H; Wang M; Zhang N; Wang J; Tan W; Wu G; Yu P; Liu H; Liu Q
Virus Res; 2023 Nov; 337():199235. PubMed ID: 37788720
[TBL] [Abstract][Full Text] [Related]
6. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.
Hu Y; Zeng G; Chu K; Zhang J; Han W; Zhang Y; Li J; Zhu F
Hum Vaccin Immunother; 2018 Jun; 14(6):1517-1523. PubMed ID: 29482422
[TBL] [Abstract][Full Text] [Related]
7. Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies.
Fu C; Lu L; Wu H; Shaman J; Cao Y; Fang F; Yang Q; He Q; Yang Z; Wang M
Sci Rep; 2016 Dec; 6():38874. PubMed ID: 27934956
[TBL] [Abstract][Full Text] [Related]
8. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
He M; Xu L; Zheng Q; Zhu R; Yin Z; Zha Z; Lin Y; Yang L; Huang Y; Ye X; Li S; Hou W; Wu Y; Han J; Liu D; Li Z; Chen Z; Yu H; Que Y; Wang Y; Yan X; Zhang J; Gu Y; Zhou ZH; Cheng T; Li S; Xia N
Cell Host Microbe; 2020 Feb; 27(2):249-261.e5. PubMed ID: 32027857
[TBL] [Abstract][Full Text] [Related]
9. Enterovirus virus-like-particle and inactivated poliovirus vaccines do not elicit substantive cross-reactive antibody responses.
Moss DL; Paine AC; Krug PW; Kanekiyo M; Ruckwardt TJ
PLoS Pathog; 2024 Apr; 20(4):e1012159. PubMed ID: 38662650
[TBL] [Abstract][Full Text] [Related]
10. Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV.
Lin CW; Chang CY; Chen WL; Lin SC; Liao CC; Chang JY; Liu CC; Hu AY; Lu TC; Chou AH; Wu SC; Chong P; Huang MH
Hum Vaccin Immunother; 2013 Nov; 9(11):2378-85. PubMed ID: 23838466
[TBL] [Abstract][Full Text] [Related]
11. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies.
Atmar RL; Ettayebi K; Ramani S; Neill FH; Lindesmith L; Baric RS; Brinkman A; Braun R; Sherwood J; Estes MK
J Infect Dis; 2024 May; 229(5):1402-1407. PubMed ID: 37781879
[TBL] [Abstract][Full Text] [Related]
12. Monitoring antigenic variations of enterovirus 71: implications for virus surveillance and vaccine development.
Chia MY; Chung WY; Chiang PS; Chien YS; Ho MS; Lee MS
PLoS Negl Trop Dis; 2014 Jul; 8(7):e3044. PubMed ID: 25058733
[TBL] [Abstract][Full Text] [Related]
13. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles.
Crawford SE; Estes MK; Ciarlet M; Barone C; O'Neal CM; Cohen J; Conner ME
J Virol; 1999 Jun; 73(6):4813-22. PubMed ID: 10233942
[TBL] [Abstract][Full Text] [Related]
14. Progress on the research and development of inactivated EV71 whole-virus vaccines.
Liang ZL; Mao QY; Wang YP; Zhu FC; Li JX; Yao X; Gao F; Wu X; Xu M; Wang JZ
Hum Vaccin Immunother; 2013 Aug; 9(8):1701-5. PubMed ID: 23744508
[TBL] [Abstract][Full Text] [Related]
15. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease.
Ong KC; Devi S; Cardosa MJ; Wong KT
J Virol; 2010 Jan; 84(1):661-5. PubMed ID: 19864378
[TBL] [Abstract][Full Text] [Related]
16. Proliferation characteristics of coxsackievirus A10 in mice and immune protection ability of experimental inactivated vaccine.
Gao W; Yue L; Yang T; Shen D; Li H; Song X; Xie T; He X; Xie Z
Biomed Pharmacother; 2021 Nov; 143():112212. PubMed ID: 34649345
[TBL] [Abstract][Full Text] [Related]
17. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines.
Lei D; Griffiths E; Martin J
Vaccine; 2020 Jul; 38(32):4917-4923. PubMed ID: 32418797
[TBL] [Abstract][Full Text] [Related]
18. The Current Status of the Disease Caused by Enterovirus 71 Infections: Epidemiology, Pathogenesis, Molecular Epidemiology, and Vaccine Development.
Chang PC; Chen SC; Chen KT
Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618078
[TBL] [Abstract][Full Text] [Related]
19. Production of antigenically stable enterovirus A71 virus-like particles in
Kingston NJ; Snowden JS; Martyna A; Shegdar M; Grehan K; Tedcastle A; Pegg E; Fox H; Macadam AJ; Martin J; Hogle JM; Rowlands DJ; Stonehouse NJ
J Gen Virol; 2023 Jun; 104(6):. PubMed ID: 37390009
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles.
Wang T; Wang C; Pang L; Zhang Y; Wang S; Liang X; Huang Z
Emerg Microbes Infect; 2024 Dec; 13(1):2337665. PubMed ID: 38551145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
